Matthias Will

Person

South San Francisco, CA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Activatable anti-PDL1 antibodies, and methods of use thereof
- Patent number 11,168,144
- Issue date Nov 9, 2021
- CytomX Therapeutics, Inc.
- Rachel Humphrey
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
CD70+ SOLID TUMOR THERAPY USING GENETICALLY ENGINEERED T CELLS TARG...
- Publication number 20230355761
- Publication date Nov 9, 2023
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- C07 - ORGANIC CHEMISTRY
Information Patent Application
RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T C...
- Publication number 20220387572
- Publication date Dec 8, 2022
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREAT...
- Publication number 20220387488
- Publication date Dec 8, 2022
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREAT...
- Publication number 20220378829
- Publication date Dec 1, 2022
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBOD...
- Publication number 20220306745
- Publication date Sep 29, 2022
- CytomX Therapeutics, Inc.
- Rachel Humphrey
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBOD...
- Publication number 20220296692
- Publication date Sep 22, 2022
- CytomX Therapeutics, Inc.
- Rachel Humphrey
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
- Publication number 20220162332
- Publication date May 26, 2022
- CytomX Therapeutics, Inc.
- Rachel Humphrey
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
- Publication number 20220023439
- Publication date Jan 27, 2022
- CytomX Therapeutics, Inc.
- Lori CARMAN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
- Publication number 20210100913
- Publication date Apr 8, 2021
- CytomX Therapeutics, Inc.
- LORI CARMAN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
- Publication number 20190117789
- Publication date Apr 25, 2019
- CytomX Therapeutics, Inc.
- LORI CARMAN
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
- Publication number 20190016814
- Publication date Jan 17, 2019
- CytomX Therapeutics, Inc.
- Rachel Humphrey
- C07 - ORGANIC CHEMISTRY

Matthias Will

Person

Patents Grantslast 30 patents

Activatable anti-PDL1 antibodies, and methods of use thereof

Patents Applicationslast 30 patents

CD70+ SOLID TUMOR THERAPY USING GENETICALLY ENGINEERED T CELLS TARG...

RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T C...

GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREAT...

GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREAT...

USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBOD...

USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBOD...

ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF

ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF

ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF

ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF

ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF